{"ok":true,"data":{"subject":{"kind":"trial","nctId":"NCT06739395","title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","sponsor":"Tianjin Medical University Second Hospital","phases":["PHASE2"],"status":"RECRUITING","indication":null,"disease":"Solid Pseudopapillary Neoplasm of the Pancreas"},"rows":[{"n":1,"question":"Is the biology right?","flags":[{"id":"somatic_driver","label":"Somatic driver evidence","value":"yes","detail":"MAP2K1 in Solid Pseudopapillary Neoplasm of the Pancreas","rule":"Open Targets has somatic-mutation evidence for the target in this cancer","source":{"label":"Open Targets: MAP2K1 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000169032/EFO_1000542","date":"2026-11-11T23:33:14.769Z"},"context":[{"figure":"2.3× relative success for targets with somatic (IntOGen) support in oncology","dataset":"Minikel et al., Nature 2024","years":"drug programs to 2023","caveat":"A ratio between groups, not a probability for this program; mostly phase 2 to 3."}]},{"id":"human_genetic","label":"Human genetic evidence","value":"yes","detail":"MAP2K1: somatic","rule":"Any germline or somatic human genetic evidence for the target in this cancer, counted apart from animal-model and literature evidence","source":{"label":"Open Targets: MAP2K1 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000169032/EFO_1000542","date":"2026-11-11T23:33:14.769Z"},"context":[{"figure":"2.6× relative probability of success, phase 1 to launch, with human genetic support","dataset":"Minikel et al., Nature 2024","years":"drug programs to 2023","caveat":"All therapy areas, mostly germline evidence; not a probability for this program."}]},{"id":"pediatric_target","label":"Pediatric target","value":"yes","detail":"KIT, MAP2K2, MAP2K1, BRAF on the FDA list","rule":"Target is on FDA's Pediatric Molecular Target List (relevant targets); membership alone neither requires nor waives a study","source":{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"},"context":[]},{"id":"haematologic","label":"Haematologic cancer","value":"no","detail":"Solid tumour","rule":"From the indication, or the registry conditions when no indication matches","source":{"label":"ClinicalTrials.gov NCT06739395","url":"https://clinicaltrials.gov/study/NCT06739395","date":"2026-11-11T23:33:14.769Z"},"context":[{"figure":"Likelihood of approval from phase 1: 7.5% haematologic vs 4.6% solid","dataset":"BIO / Informa / QLS 2021","years":"2011–2020","caveat":"Population-level, not a prediction."}]}],"facts":[{"label":"Background therapy","text":"Temozolomide: standard agents, not counted in these flags."},{"label":"PARP1 (via Olaparib)","text":"Open Targets has no association between PARP1 and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: PARP1 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000143799/EFO_1000542","date":"2026-11-11T23:33:14.769Z"}},{"label":"PARP3 (via Olaparib)","text":"Open Targets has no association between PARP3 and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: PARP3 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000041880/EFO_1000542","date":"2026-11-11T23:33:14.769Z"}},{"label":"PARP2 (via Olaparib)","text":"Open Targets has no association between PARP2 and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: PARP2 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000129484/EFO_1000542","date":"2026-11-11T23:33:14.769Z"}},{"label":"KDR (via Anlotinib)","text":"Open Targets has no association between KDR and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: KDR in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000128052/EFO_1000542","date":"2026-11-11T23:33:14.769Z"}},{"label":"FLT4 (via Anlotinib)","text":"Open Targets has no association between FLT4 and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: FLT4 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000037280/EFO_1000542","date":"2026-11-11T23:33:14.769Z"}},{"label":"KIT (via Anlotinib)","text":"Evidence types in Solid Pseudopapillary Neoplasm of the Pancreas: literature; literature listed separately from human genetics. Datasources: europepmc.","source":{"label":"Open Targets: KIT in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000157404/EFO_1000542","date":"2026-11-11T23:33:14.769Z"}},{"label":"MAP2K2 (via Trametinib)","text":"Open Targets has no association between MAP2K2 and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: MAP2K2 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000126934/EFO_1000542","date":"2026-11-11T23:33:14.769Z"}},{"label":"MAP2K1 (via Trametinib)","text":"Evidence types in Solid Pseudopapillary Neoplasm of the Pancreas: somatic_mutation. Datasources: cancer_gene_census.","source":{"label":"Open Targets: MAP2K1 in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000169032/EFO_1000542","date":"2026-11-11T23:33:14.769Z"}},{"label":"BRAF (via Dabrafenib)","text":"Open Targets has no association between BRAF and Solid Pseudopapillary Neoplasm of the Pancreas.","source":{"label":"Open Targets: BRAF in Solid Pseudopapillary Neoplasm of the Pancreas","url":"https://platform.opentargets.org/evidence/ENSG00000157764/EFO_1000542","date":"2026-11-11T23:33:14.769Z"}}],"pending":[{"what":"Normal-tissue expression in vital organs","source":"Human Protein Atlas (ticket 36)"},{"what":"Pan-essential in cell lines","source":"DepMap (ticket 36)"},{"what":"Approved drug on this target","source":"Drugs@FDA (ticket 30)"}]},{"n":2,"question":"Can the result be trusted?","flags":[{"id":"randomised","label":"Randomised","value":"no","detail":"Non-randomised","rule":"Registry allocation field","source":{"label":"ClinicalTrials.gov NCT06739395","url":"https://clinicaltrials.gov/study/NCT06739395","date":"2026-11-11T23:33:14.769Z"},"context":[]},{"id":"small_denominator","label":"Small denominator","value":"no","detail":"300 planned; each patient moves a rate by 100 ÷ 300 = 0.3 points","rule":"Enrolment under 30; the arithmetic is shown, not a benchmark","source":{"label":"ClinicalTrials.gov NCT06739395","url":"https://clinicaltrials.gov/study/NCT06739395","date":"2026-11-11T23:33:14.769Z"},"context":[]},{"id":"primary_os","label":"Primary endpoint is overall survival","value":"no","detail":"PFS2/PFS1(Progression Free Survival 2/Progression Free Survival 1)","rule":"A registered primary outcome measure names overall survival","source":{"label":"ClinicalTrials.gov NCT06739395","url":"https://clinicaltrials.gov/study/NCT06739395","date":"2026-11-11T23:33:14.769Z"},"context":[{"figure":"Non-OS primary endpoint: odds ratio 2.79 for a positive phase 3","dataset":"Otsuka 2021, 400 phase 3 oncology trials","years":"to 2020","caveat":"Shown with the next figure: a surrogate is easier to hit, and often a weak guide to survival."},{"figure":"52% of surrogate-to-OS correlations are low","dataset":"Prasad 2015","years":"published to 2014","caveat":"Shown with the figure above."}]},{"id":"results_overdue","label":"Results overdue","value":"no","detail":"Primary completion expected 2026-12-31; not yet due","rule":"Primary completion (actual) more than 12 months ago and no results posted to the registry","source":{"label":"ClinicalTrials.gov NCT06739395","url":"https://clinicaltrials.gov/study/NCT06739395","date":"2026-11-11T23:33:14.769Z"},"context":[]}],"facts":[],"pending":[{"what":"Treated and evaluable counts, assessor, confirmed response, follow-up and data cutoff","source":"Readout extraction (ticket 32)"},{"what":"Primary endpoint changed between registry versions","source":"Registry versions in the store (ticket 32)"}]},{"n":3,"question":"What must it beat?","flags":[],"facts":[],"pending":[{"what":"Control-arm result and approved therapies for the same segment, with label links","source":"Drugs@FDA, FDA labels and readouts (tickets 30, 32)"}]},{"n":4,"question":"Too crowded, or too late?","flags":[],"facts":[{"label":"Stopped on this target","text":"164 terminated, withdrawn or suspended trials of drugs against PARP1; 9 give no reason. Reasons are quoted as the registry gives them on the target page.","source":{"label":"PARP1: what already stopped","url":"/target/ENSG00000143799#stopped","date":"2026-11-11T23:33:14.811Z"}}],"pending":[{"what":"Programs on the target by phase and months behind the leader","source":"Programs and Drugs@FDA (ticket 33)"}]},{"n":5,"question":"Can it be approved, and stay approved?","flags":[{"id":"single_country","label":"Single-country","value":"yes","detail":"The only site is in China","rule":"All listed sites are in one country; the share of US sites is shown","source":{"label":"ClinicalTrials.gov NCT06739395","url":"https://clinicaltrials.gov/study/NCT06739395?tab=locations","date":"2026-11-11T23:33:14.769Z"},"context":[]},{"id":"eu_pip","label":"EU paediatric investigation plan","value":"yes","detail":"EMEA-002269-PIP01-17-M03 (olaparib, Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)): PM: decision on the application for modification of an agreed PIP, 6 May 2024; EMEA-001147-PIP02-20 (dabrafenib, Treatment of glioma): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 23 Oct 2020; compliance positive 27 Sept 2022; EMEA-001177-PIP02-20 (trametinib, Treatment of glioma): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 23 Oct 2020; compliance positive 27 Sept 2022; EMEA-001147-PIP01-11-M07 (dabrafenib mesilate, Treatment of melanoma;Treatment of solid malignant tumours (excluding melanoma)): PM: decision on the application for modification of an agreed PIP, 23 Oct 2020; compliance positive 11 Nov 2022","rule":"An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-paediatric_investigation_plans-output-json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_orphan","label":"EU orphan designation","value":"yes","detail":"EU/3/20/2372 positive 9 Dec 2020: Treatment of glioma; EU/3/20/2374 positive 9 Dec 2020: Treatment of glioma; EU/3/07/501 withdrawn 6 Dec 2007: Treatment of ovarian cancer","rule":"An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-orphan_designations-json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_authorised","label":"Authorised in the EU","value":"yes","detail":"Lynparza: authorised since 16 Dec 2014; Mekinist: authorised since 30 Jun 2014; Tafinlar: authorised since 26 Aug 2013; Spexotras: authorised since 5 Jan 2024, orphan medicine; +1 more","rule":"An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"fda_orphan","label":"FDA orphan designation","value":"not published","detail":"FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link","rule":"Would be: an FDA orphan designation names the drug","source":{"label":"FDA orphan designations search","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/","date":""},"context":[]},{"id":"fda_ped_approval","label":"FDA pediatric oncology approval","value":"yes","detail":"Trametinib [Mekinist], 31 Aug 2023: In combination with dabrafenib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options; Trametinib [Mekinist], 16 Mar 2023: In combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy; Dabrafenib [Tafinlar], 31 Aug 2023: In combination with trametinib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options; +1 more","rule":"FDA's Pediatric Oncology Drug Approvals table names the drug","source":{"label":"FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03)","url":"https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals","date":"2026-11-11T23:33:14.832Z"},"context":[]},{"id":"studies_under_18","label":"Registered studies open to children","value":"yes","detail":"86 interventional studies of Olaparib, Anlotinib, Trametinib, Dabrafenib include patients under 18; 53 are recruiting, not yet recruiting or active","rule":"The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age","source":{"label":"ClinicalTrials.gov search","url":"https://clinicaltrials.gov/search?intr=%22Olaparib%22+OR+%22Anlotinib%22+OR+%22Trametinib%22+OR+%22Dabrafenib%22&aggFilters=ages%3Achild%2CstudyType%3Aint","date":"2026-11-11T23:33:14.842Z"},"context":[]}],"facts":[{"label":"Caveat","text":"Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where the sites are is a fact about the record, not a judgement of its quality."},{"label":"Cited case","text":"In February 2022 FDA asked its Oncologic Drugs Advisory Committee whether sintilimab's application, resting on ORIENT-11, a phase 3 run only in China, needed further trials showing it applies to US patients and US practice. One case, not a rule.","source":{"label":"FDA, ODAC 10 Feb 2022, draft questions","url":"https://www.fda.gov/media/156017/download","date":"2022-02-10"}},{"label":"Rare pediatric disease voucher","text":"FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news.","source":{"label":"FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs","url":"https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs","date":"2026-11-11"}}],"pending":[{"what":"Precedent approvals for target, modality and endpoint; accelerated-approval status","source":"Drugs@FDA and FDA accelerated-approval tables (ticket 30)"}]},{"n":6,"question":"Can the sponsor finish?","flags":[],"facts":[{"label":"Sponsor","text":"Tianjin Medical University Second Hospital (academic or other)","source":{"label":"ClinicalTrials.gov NCT06739395","url":"https://clinicaltrials.gov/study/NCT06739395","date":"2026-11-11T23:33:14.769Z"}},{"label":"principal investigator","text":"Haitao Wang, Ph.D, Tianjin Medical University Second Hospital","source":{"label":"Person page","url":"/person/Haitao%20Wang%2C%20Ph.D","date":"2026-11-11T23:33:14.769Z"}}],"pending":[{"what":"Filed cash, quarterly spend and the runway arithmetic","source":"SEC XBRL company facts (ticket 37)"},{"what":"Sponsor's completed vs stopped oncology trials and results-reporting record","source":"Registry, by company (ticket 37)"}]}],"limits":"Public records cannot show: sales forecasts; a probability of success for this asset; full deal terms and net prices; FDA designations and action dates before approval (shown only as company-reported); clinical holds unless the company disclosed them; manufacturing; patents on unapproved drugs; whether preclinical findings have been replicated.","sources":[{"label":"ClinicalTrials.gov NCT06739395","url":"https://clinicaltrials.gov/study/NCT06739395","date":"2026-11-11T23:33:14.769Z"},{"label":"Open Targets Platform","url":"https://platform.opentargets.org","date":"2026-11-11T23:33:14.769Z"},{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"}]},"source":"ClinicalTrials.gov + Open Targets","fetchedAt":"2026-11-11T23:33:14.766Z"}